Business
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET PORTLAND, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC)
About this update from Immucell Corporation
[{"type":"text","content":"Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET\nPORTLAND, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2022 after the market closes on Thursday, May 12, 2022. The Company has scheduled a conference call the next morning, Friday, May 13, 2022, at 9:00 AM ET to review the financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available for seven days at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing confirmation #6767746. Dr. Joseph H. Crabb, former Chief Scientific Officer and VP of Product Development and current consultant to the Company, is expected to join the call to discuss the Company’s core science and technology. The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Thursday, May 12, 2022. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which will be posted under the “Investors” tab of the Company’s website at www.immucell.com after the market closes on Thursday, May 12, 2022, or by request to the Company. About ImmuCell:ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com. Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):This Press Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and S...